Press Releases Year All20242023202220212020201920182017201620152014 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Feb 05, 2024 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024 INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Jan 04, 2024 Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 03, 2024 Coherus Announces U.S. Launch of LOQTORZI™ Jan 02, 2024
Year All20242023202220212020201920182017201620152014 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Feb 05, 2024 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024 INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Jan 04, 2024 Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 03, 2024 Coherus Announces U.S. Launch of LOQTORZI™ Jan 02, 2024
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Jan 04, 2024
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 03, 2024